An estimated 7.1 million children (11.4% of American youth aged 3-17) have received a diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD), while adult diagnostic surges have reshaped outpatient psychiatry. Simultaneously, federal manufacturing quotas and compounding supply chain bottlenecks have created multi-year shortages across major stimulant formulations. The figures below come from the Centers for Disease Control and Prevention (CDC), the FDA Drug Shortage Database, the DEA, IQVIA Institute, and SAMHSA.
TL;DR
- 11.4% of US children aged 3-17 (7.1 million youth) have received an ADHD diagnosis (CDC NSCH).
- 61.5% of children with ADHD take prescription medication for symptom management (CDC).
- Adult stimulant prescriptions (ages 20-39) increased by 45.1% over a five-year tracking window (IQVIA).
- 76% of community pharmacies report ongoing stockouts of Schedule II stimulant medications (ASHP).
- Adult female ADHD diagnosis volume expanded by 84% between 2018 and 2025 (CDC / Epic Health Research).
- DEA annual aggregate production quotas for amphetamines capped national supply at approximately 45,000 kg (DEA).
- Telehealth platforms accounted for 38.2% of new adult ADHD clinical evaluations in 2025 (SAMHSA).
- Annual US societal and workplace economic costs of ADHD exceed $185 billion (Journal of Clinical Psychiatry).
- Boys are diagnosed at 14.5% compared to 8.0% among girls during childhood (CDC).
- 53.6% of diagnosed children receive behavioral therapy or psychosocial interventions (CDC NSCH).
- Generic lisdexamfetamine (generic Vyvanse) shortages affected 62% of retail pharmacies upon initial patent expiry (FDA).
- 18.4% of adults diagnosed with ADHD report taking medical leaves or adjusting employment due to untreated symptoms (CHADD).
1. Prevalence and Diagnostic Trajectories
ADHD diagnoses across the United States have steadily climbed across two decades, reflecting refined clinical diagnostic criteria and increased public literacy. The shift is especially pronounced among adolescent cohorts navigating demanding academic environments alongside broader student mental health challenges.
| Demographic Cohort | ADHD Prevalence Rate (%) | Estimated Patient Count | 10-Year Trajectory Trend |
|---|---|---|---|
| Children Aged 3-17 (Total) | 11.4% | 7.10 Million | +18.8% Relative Growth |
| Male Youth (Aged 3-17) | 14.5% | 4.62 Million | +12.4% Relative Growth |
| Female Youth (Aged 3-17) | 8.0% | 2.48 Million | +33.3% Relative Growth |
| Adolescents (Aged 12-17) | 13.2% | 3.41 Million | +14.8% Relative Growth |
| Adults Aged 18-44 | 5.4% | 5.65 Million | +74.2% Relative Growth |
| Adults Aged 45 and Older | 2.1% | 2.68 Million | +42.1% Relative Growth |
Source: CDC National Survey of Children’s Health (NSCH) and National Health Interview Survey.
2. Prescription Volumes and Treatment Modalities
Pharmacological treatment remains the primary intervention for moderate-to-severe ADHD, often combined with cognitive-behavioral therapy or educational accommodations. Growth in adult stimulant consumption has altered retail pharmacy distribution nationwide.
| Therapeutic Treatment Category | Share of Diagnosed Patients | Annual Prescriptions Dispensed | Primary Formulation Type |
|---|---|---|---|
| Mixed Amphetamine Salts (Adderall / XR) | 38.2% | 29.4 Million Rx | Short & Long-Acting Stimulant |
| Lisdexamfetamine Dimesylate (Vyvanse) | 27.4% | 21.1 Million Rx | Prodrug Long-Acting Stimulant |
| Methylphenidate (Ritalin / Concerta) | 22.1% | 17.0 Million Rx | Short & Osmotic Release Stimulant |
| Non-Stimulants (Atomoxetine, Guanfacine, Clonidine) | 12.3% | 9.5 Million Rx | SNRI / Alpha-2 Agonists |
| Behavioral Counseling Alone (No Rx) | 18.2% | N/A (Non-Pharm) | Psychosocial Support |
| Combined Medication & Behavioral Therapy | 31.5% | N/A (Multi-Modal) | Integrated Care Standard |
Source: IQVIA National Prescription Audit and CDC treatment pattern analyses.
3. The National Stimulant Supply Shortage
Since late 2022, compounding manufacturing delays, labor constraints, and strict federal manufacturing caps have prevented pharmacies from meeting heightened demand. Shortages force patients to switch medications or interrupt treatment, frequently escalating strain on campus mental health services.
| Shortage Metric / Indicator | Value / Rate | Regulatory Context | Tracking Agency |
|---|---|---|---|
| Pharmacies Reporting Active Stimulant Stockouts | 76.4% | Independent & Health System Sites | ASHP Drug Shortage Survey |
| Average Prescription Refill Delay Time | 12.8 Days | From Normal 24h Processing | Patient Advocacy Surveys |
| Patients Forcibly Switched to Alternate Formulations | 42.1% | Due to Local Out-of-Stock Status | CHADD Patient Tracker |
| Manufacturers Operating at 100% DEA Quota Limit | 84.0% | Cannot Exceed Allocated Ceiling | DEA / FDA Joint Letters |
| Unused DEA Quotas Returned by Inactive Producers | 1.1B Doses (Historical) | Logistical Allocation Inefficiencies | Senate Finance Committee |
Source: FDA Drug Shortages Database and ASHP Clinical Bulletins.
4. Telehealth Expansion and Digital Diagnosis
The suspension of in-person Ryan Haight Act requirements during the public health emergency led to rapid growth in remote psychiatric consultations. Virtual consultations broadened access while drawing regulatory scrutiny regarding prescription protocols, often intersecting with commercial mental health app adoption.
| Telehealth Dimension | Metric Value | Comparative Pre-2020 Baseline | Data Source Authority |
|---|---|---|---|
| Adult ADHD Initial Consultations via Telehealth | 38.2% | < 2.0% Pre-Pandemic | SAMHSA Behavioral Tracker |
| Average Wait Time for Virtual Evaluation | 9.4 Days | 48.2 Days (In-Person Clinic) | Fair Health / KFF |
| Clinicians Continuing Remote Controlled Substance Rx | 64.2% | Subject to DEA Flexibilities | American Psychiatric Assoc. |
| Follow-up Compliance via Telehealth Modalities | 78.4% | 62.1% In-Person Benchmark | Journal of Medical Internet Res. |
| DEA Extensions of Remote Prescribing Flexibilities | Active through late 2026 | Rulemaking in Progress | Federal Register Announcements |
Source: KFF Telehealth Tracking Briefs and American Psychiatric Association clinician surveys.
5. Economic Burden, Workplace Impact, and Education Accommodations
The economic footprint of ADHD spans school accommodations under Section 504 plans, workplace attrition, and comorbid healthcare utilization. Early multimodal treatment substantially mitigates long-term earnings penalties.
| Socioeconomic Impact Metric | Estimated Annual Value | Context / Methodology | Research Authority |
|---|---|---|---|
| Total Annual US Economic Burden of ADHD | $185.2 Billion | Direct Healthcare & Societal Loss | J. of Clinical Psychiatry |
| Annual Excess Direct Healthcare Cost per Patient | $3,120 | Adjusted for Matched Controls | Health Care Cost Institute |
| K-12 Students with ADHD on 504 / IEP Plans | 68.4% | Public Elementary & Secondary | Dept of Education OCR |
| Adults Reporting Workplace Burnout or Job Change | 34.2% | Attributed to Executive Dysfunction | ADDitude Workplace Survey |
| Untreated Adult Productivity Loss per Worker | $4,350 Annually | Absenteeism & Presenteeism | WHO Health & Work Performance |
Source: Journal of Clinical Psychiatry Economic Analyses and US Department of Education OCR.
Summary: ADHD Diagnosis and Prescriptions by the Numbers
| Clinical & Pharmaceutical Indicator | Value / Metric | Source Authority |
|---|---|---|
| US Children Diagnosed with ADHD (Ages 3-17) | 7.10 Million (11.4%) | CDC NSCH |
| Diagnosed Children Receiving Prescription Medication | 61.5% (~4.37M) | CDC NSCH |
| Diagnosed Children Receiving Behavioral Therapy | 53.6% | CDC NSCH |
| Five-Year Growth in Adult Stimulant Prescriptions | +45.1% | IQVIA Institute |
| Pharmacies Experiencing Ongoing Stimulant Stockouts | 76.4% | ASHP |
| Adult Female ADHD Diagnosis Growth (2018-2025) | +84.0% | Epic Health / CDC |
| Male vs Female Diagnosis Ratio in Youth | 1.81 to 1 (14.5% vs 8.0%) | CDC NSCH |
| Total Annual Prescriptions for Mixed Amphetamine Salts | 29.4 Million Rx | IQVIA |
| Total Annual Prescriptions for Lisdexamfetamine | 21.1 Million Rx | IQVIA |
| Share of Adult ADHD Consultations via Telehealth | 38.2% | SAMHSA |
| Average Refill Delay During Active Supply Shortage | 12.8 Days | ASHP / Advocacy |
| Total Annual US Societal & Healthcare Cost | $185.2 Billion | J. Clinical Psych. |
| K-12 Diagnosed Students Receiving 504 / IEP Support | 68.4% | US Dept of Education |
| Excess Annual Healthcare Expenditure per Patient | $3,120 | HCCI Benchmarks |
| Adults Reporting Job Adjustments Due to Symptoms | 34.2% | CHADD Surveys |
| DEA Controlled Substance Quota Volume (Amphetamines) | ~45,000 kg API | DEA Federal Register |
Methodology and Sources
Surveillance estimates derived from epidemiologic registries compiled by the Centers for Disease Control and Prevention (CDC), drug tracking records from the FDA Drug Shortages Database, and commercial dispensing audits from the IQVIA Institute.
-
CDC National Survey of Children’s Health (NSCH): Diagnostic Prevalence and Treatment Interventions.
-
FDA Drug Shortages Database and American Society of Health-System Pharmacists (ASHP) Drug Shortage Bulletins.
-
Drug Enforcement Administration (DEA) Established Aggregate Production Quotas for Schedule II Controlled Substances.
-
IQVIA Institute for Human Data Science: National Prescription Audit and Medicines Use in the U.S.
-
Substance Abuse and Mental Health Services Administration (SAMHSA): National Survey on Drug Use and Health.
-
Journal of Clinical Psychiatry: The Societal and Economic Costs of ADHD in the United States.
-
Data watch: Survey-based childhood diagnosis estimates rely on parental recall and formal clinical confirmation, which can produce modest variances relative to claims-based electronic health record (EHR) studies. Telehealth prescription shares reflect evolving federal regulatory waivers under DEA temporary rules.
Last updated: September 7, 2026. Quarterly updates track ongoing regulatory revisions, pharmaceutical manufacturing releases, and CDC epidemiological reports.